Cilofexor (GS-9674) 是一种有效的,选择性的,口服活性的非甾体 FXR 激动剂,EC50 为 43 nM。。在一项为期 12 周的研究中,Cilofexor 在原发性硬化性胆管炎患者中耐受良好,并显著改善了肝生化指标和胆汁淤积标志物。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Cilofexor is a nonsteroidal FXR agonist. Cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with primary sclerosing cholangitis in a 12-week study. |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6JOlaHSD mice | Cholestatic liver injury model | Oral gavage | 30 mg/kg | Once daily for 3 weeks | Cilofexor monotherapy and combination therapy with ASBTi ameliorated cholestatic liver injury, reduced plasma ALT and AST levels, and decreased liver inflammation and fibrosis markers. | JHEP Rep. 2023 Sep 25;6(1):100917 |
| Wistar rats | NASH model | Oral | 10 mg/kg and 30 mg/kg | Dose adjusted weekly, lasting for 6 weeks | To evaluate the effect of Cilofexor on portal hypertension and hepatic fibrosis in NASH rats, results showed that Cilofexor significantly reduced portal pressure and hepatic fibrosis. | Biomedicines. 2021 Jan 9;9(1):60 |
| Mice | Mdr2-/- mouse model | Gavage | 0, 10, 30, or 90 mg/kg | Every 24 hours for 10 weeks | To evaluate the anti-cholestatic, anti-inflammatory, and anti-fibrotic effects of cilofexor in the Mdr2-/- mouse model. Results showed that cilofexor improved serum biochemistry, reduced hepatic fibrosis, and decreased serum and intrahepatic bile acid levels. | JHEP Rep. 2023 Aug 3;5(11):100874 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.70mL 0.34mL 0.17mL |
8.52mL 1.70mL 0.85mL |
17.04mL 3.41mL 1.70mL |
|
| CAS号 | 1418274-28-8 |
| 分子式 | C28H22Cl3N3O5 |
| 分子量 | 586.85 |
| SMILES Code | O=C(C1=CC(N2CC(O)(C3=CC=C(OCC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)C=C3Cl)C2)=NC=C1)O |
| MDL No. | MFCD31731099 |
| 别名 | GS-9674 |
| 运输 | 蓝冰 |
| InChI Key | KZSKGLFYQAYZCO-UHFFFAOYSA-N |
| Pubchem ID | 71228883 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 50 mg/mL(85.2 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1